ClinicalTrials.gg
Enrolling by invitationNCT06216275sn/dmUpdated Feb 6, 2024

Enhancing Calm in Arab Elderly With Dementia

An interventional study of Integrated Snoezelen-Aromatherapy-Personal Item Therapy in Dementia and Agitation in Dementia, Including Alzheimer's Disease, sponsored by Mostafa Shaban. Enrolling by invitation at 1 site in Egypt. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-02-06.

Sponsored by Mostafa Shaban · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the effectiveness of integrating Snoezelen methods with aromatherapy and personal items in reducing agitation in Arab elderly individuals with dementia. The main questions it aims to answer are:

Does the combination of Snoezelen methods, aromatherapy, and the use of personal items significantly reduce agitation in elderly Arab patients with dementia compared to standard care practices? How do patients and caregivers perceive the impact of this integrated approach on the overall well-being and quality of life of the patients?

Participants in this study will:

Engage in sessions utilizing Snoezelen methods, a multi-sensory environment designed to deliver stimuli to various senses.

Receive aromatherapy treatments with selected scents known for their calming properties.

Be provided with personal items that are familiar and meaningful to them, to create a sense of comfort and security.

Read the detailed description

This clinical trial is centered on a novel approach to dementia care, specifically targeting the Arab elderly demographic. It uniquely combines three elements - Snoezelen therapy, aromatherapy, and the use of personal items - to address agitation, a common and challenging symptom in dementia patients.

Snoezelen Therapy Implementation:

Custom-designed Snoezelen rooms will be used, equipped with lights, colors, sounds, and textures to stimulate senses in a controlled manner.

Sessions will be tailored to individual patient needs and preferences, monitored by trained staff.

Aromatherapy Application:

Selection of aromas will be based on their known calming properties, with a focus on cultural relevance and acceptability in the Arab elderly population.

The method of delivery and duration of each aromatherapy session will be standardized to ensure consistency across the study.

Incorporation of Personal Items:

Patients will be encouraged to select personal items that hold significant emotional value or are tied to pleasant memories.

These items will be integrated into the therapy sessions to provide a sense of familiarity and emotional comfort.

Data Collection and Analysis:

Quantitative data on agitation levels will be gathered using established agitation scales, both pre- and post-intervention.

The study aims to provide a comprehensive evaluation of how this integrated approach can influence agitation in dementia, considering both statistical effectiveness and personal experiences. The outcome will contribute valuable insights into dementia care practices, particularly for the Arab elderly population, and may offer a template for culturally sensitive dementia care.

02

Conditions studied

  • Dementia
  • Agitation in Dementia, Including Alzheimer's Disease

Browse trials for

Keywords

  • Dementia Care
  • Agitation in Elderly
  • Arab Elderly Dementia
  • Snoezelen Therapy
  • Aromatherapy in Dementia
  • Multi-sensory Stimulation
03

In context

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

This study's planned enrollment of 80 is below the median of 90 across 1,761 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

Mostafa Shaban is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For the study \"Enhancing Calm in Arab Elderly with Dementia: Integrating Snoezelen Methods with Aromatherapy and Personal Items to Reduce Agitation\", here are the suggested Inclusion and Exclusion Criteria:

Inclusion criteria

Inclusion Criteria:

  • Age: Participants must be 65 years to 90 years
  • Diagnosis: Clinical diagnosis of dementia required.
  • Ethnicity: Must be of Arab descent.
  • Agitation Levels: Must show agitation signs based on a standardized scale.
  • Cognitive Function: Adequate cognitive function for study participation, verified by standard assessment.

Exclusion criteria

Exclusion Criteria:

  • Severe Medical Conditions: Individuals with severe medical conditions that could affect study participation or health.
  • Advanced Dementia: Patients with very advanced dementia stages, unable to engage in study activities.
  • Allergies: Known allergies to aromatherapy products used in the study.
  • Recent Medication Changes: Significant changes in dementia medication regimen before the study.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Participants receiving the integrated approach of Snoezelen therapy, aromatherapy, and the use of personal items.

    Behavioral: Integrated Snoezelen-Aromatherapy-Personal Item Therapy

  • No intervention
    Control Arm

    Participants receiving standard care practices for dementia and agitation without the integrated approach.

Interventions

  • BehavioralIntegrated Snoezelen-Aromatherapy-Personal Item Therapy

    Intervention Description: This unique intervention combines three distinct therapeutic approaches specifically tailored for Arab elderly patients with dementia experiencing agitation. Snoezelen Therapy: Customized sessions in a Snoezelen environment - a specialized room designed to deliver controlled multi-sensory stimuli. This room features adaptable lighting, colors, sounds, and textures to provide a soothing and stimulating experience. Sessions are personalized based on each patient's response and preference, under the guidance of trained professionals. Aromatherapy: Carefully selected essential oils known for their calming properties are used in a culturally sensitive manner. These oils are diffused in the environment or used during individual sessions to provide a relaxing olfactory experience. The choice of oils and method of delivery are standardized

06

What researchers measure

Primary outcomes

  1. Reduction in Agitation Levels

    The primary outcome measure is the reduction in agitation levels among the Arab elderly with dementia participating in the study. This will be quantitatively assessed using a validated agitation scale, such as the Cohen-Mansfield Agitation Inventory (CMAI) or a similar tool appropriate for dementia patients.

    Time frame: 4 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Smith BC, D'Amico M. Sensory-Based Interventions for Adults with Dementia and Alzheimer's Disease: A Scoping Review. Occup Ther Health Care. 2020 Jul;34(3):171-201. doi: 10.1080/07380577.2019.1608488. Epub 2019 May 8. PubMed 31066598 ↗
  • Hogg J, Cavet J, Lambe L, Smeddle M. The use of 'Snoezelen' as multisensory stimulation with people with intellectual disabilities: a review of the research. Res Dev Disabil. 2001 Sep-Oct;22(5):353-72. doi: 10.1016/s0891-4222(01)00077-4. PubMed 11580163 ↗
  • Burns I, Cox H, Plant H. Leisure or therapeutics? Snoezelen and the care of older persons with dementia. Int J Nurs Pract. 2000 Jun;6(3):118-26. doi: 10.1046/j.1440-172x.2000.00196.x. PubMed 11249409 ↗
  • Merrick J, Cahana C, Lotan M, Kandel I, Carmeli E. Snoezelen or controlled multisensory stimulation. Treatment aspects from Israel. ScientificWorldJournal. 2004 May 11;4:307-14. doi: 10.1100/tsw.2004.30. PubMed 15167944 ↗
  • Chitsey AM, Haight BK, Jones MM. Snoezelen: a multisensory environmental intervention. J Gerontol Nurs. 2002 Mar;28(3):41-9. doi: 10.3928/0098-9134-20020301-09. PubMed 11913515 ↗
  • Carvalho SC, Martins FS, Martins AN, Barbosa RC, Vicente SG. Effectiveness of Snoezelen in older adults with neurocognitive and other pathologies: A systematic review of the literature. J Neuropsychol. 2024 Jun;18(2):312-331. doi: 10.1111/jnp.12346. Epub 2023 Sep 21. PubMed 37735859 ↗
  • Seegers H, Serani I, Bogar M, Gei M, Baudet V, Witz L, Bouchard JP. [The Snoezelen approach in pain management in psychiatry]. Soins Psychiatr. 2019 Jan-Feb;40(320):35-40. doi: 10.1016/j.spsy.2018.11.008. French. PubMed 30654878 ↗
  • Chung JC, Lai CK, Chung PM, French HP. Snoezelen for dementia. Cochrane Database Syst Rev. 2002;2002(4):CD003152. doi: 10.1002/14651858.CD003152. PubMed 12519587 ↗
  • Sigal A, Sigal M. The Multisensory/Snoezelen Environment to Optimize the Dental Care Patient Experience. Dent Clin North Am. 2022 Apr;66(2):209-228. doi: 10.1016/j.cden.2021.12.001. PubMed 35365274 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Feb 2024, 0 months after the start.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 0 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 22, 2024
StartActual
Jan 5, 2024
Primary completionEst.
Feb 1, 2024
CompletionEst.
Mar 1, 2024
Last update
Feb 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06216275
Lead sponsor
Mostafa Shaban
Responsible party
Mostafa Shaban (Lecturer, Cairo University) — Sponsor-investigator
First posted
Jan 22, 2024
Start date
Jan 5, 2024
Primary completion
Feb 1, 2024 (estimated)
Completion
Mar 1, 2024 (estimated)
Last update
Feb 6, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion